araag2/HINT huggingface dataset:
Clinical trial NCT01440127 (phase 1, status: terminated)
Conditions: colon cancer
ICD codes: C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3
Drugs: metformin
SMILES: CSCC[C@H](N)C(O)=O
Reason stopped: 
    unable to accrue all planned subjects in a timely fashion, but data collected will still be
    analyzed.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically documented colorectal cancer

          -  Intent to undergo disease resection or biopsy at least 7days from the treatment start
             date (allowing for a minimum of 5 days of treatment plus 2 days break)

          -  Medically fit for resection of their primary tumor or for biopsy

          -  Age 18-79 years

          -  Adequate renal function (serum creatinine levels <1.5 mg/dL [males], <1.4 mg/dL
             [females] or estimated creatinine clearance >= 60 ml/min)

          -  Adequate hepatic parameters, including aspartate aminotransferase (AST) and alanine
             aminotransferase (ALT) levels ≤ 2.5 x upper limit of normal (ULN), total bilirubin ≤
             1.5 x ULN, and alkaline phosphatase levels ≤ 2.5 x ULN

          -  Ability to understand and willingness to sign a written informed consent document

        Exclusion Criteria:

          -  Intent to administer neoadjuvant chemotherapy or radiation therapy prior to the
             surgery or biopsy;

          -  Intent to perform surgery or biopsy within 7 days of study treatment start;

          -  Any situation where participation in this trial would alter, or cause significant risk
             of altering the ability or timing of a subject to undergo resection of their tumor

          -  Current use of metformin (within the past month);

          -  Blood glucose using point of care test < 70mg/dl;

          -  Renal disease or renal dysfunction not meeting inclusion criteria;

          -  Significant medical conditions such as cardiovascular collapse (shock), acute
             myocardial infarction, septicemia, acute or chronic metabolic acidosis

          -  History of, or states associated with, lactic acidosis such as shock or pulmonary
             insufficiency, alcoholism (acute or chronic), conditions associated with hypoxemia and
             pancreatitis

          -  Severe dehydration

          -  Clinical or laboratory evidence of hepatic disease

          -  Congestive heart failure requiring pharmacologic treatment, or unstable or acute
             congestive heart failure

          -  Known hypersensitivity to metformin hydrochloride

          -  Pregnant or lactating women

          -  Psychiatric illness or social situation that would limit compliance with study
             requirements and/or obscure results
Clinical trial NCT00496028 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: azd0530, carboplatin, paclitaxel
SMILES: CN1CCN(CCOC2=CC3=C(C(NC4=C(Cl)C=CC5=C4OCO5)=NC=N3)C(OC3CCOCC3)=C2)CC1, N[C@@H](CCCNC(N)=N)C(O)=O, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC
Eligibility criteria:

        Inclusion Criteria:

          -  Life expectancy > 12 weeks

          -  Women defined as post-menopausal

          -  Male or female patients with locally advanced or metastatic cancer suitable for
             treatment with carboplatin and/or paclitaxel

        Exclusion Criteria:

          -  Inadequate bone marrow reserve

          -  Inadequate live function, renal function or low haemoglobin

          -  Unresolved toxicity from anti-cancer therapy
Clinical trial NCT00532090 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: rg4733, rg4733, rg4733
SMILES: CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CC=C2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CC=C2NC1=O, CC(C)(C(=O)NCC(F)(F)C(F)(F)F)C(=O)N[C@H]1C2=CC=CC=C2C2=CC=CC=C2NC1=O
Eligibility criteria:

        Inclusion Criteria:

          -  adult patients, >=18 years of age;

          -  advanced and/or metastatic solid tumor malignancy;

          -  measurable or evaluable disease;

          -  ECOG performance status 0 or 1.

        Exclusion Criteria:

          -  prior chemotherapy, radiotherapy or immunotherapy within 28 days of first receipt of
             study drug;

          -  prior corticosteroids as anti-cancer therapy within a minimum of 14 days of first
             receipt of study drug. Dexamethasone may be allowed only as part of the supportive
             care measures;

          -  major surgery within 28 days of first receipt of study drug.
Clinical trial NCT00378404 (phase 1, status: terminated)
Conditions: non-small cell lung cancer
ICD codes: C78.00, C78.01, C78.02, D14.30, D14.31, D14.32, C34.2
Drugs: docetaxel
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must be 18 years of age or greater.

          -  Histologically or cytologically proven non-small cell lung cancer that is either
             metastatic or recurrent and failed at least one prior platinum-based chemotherapeutic
             regimen.

          -  Patients who have recurred after previous surgery and/or radiation may participate in
             this trial.

          -  Patients may have had prior neoadjuvant or adjuvant therapy.

          -  Patients with known brain metastases are eligible for this clinical trial if their
             disease has been treated and they are clinically stable and documented by a stable or
             improved pretreatment CT or MRI scan of the brain to evaluate for CNS disease within
             28 days prior to registration.

          -  Measurable OR non-measurable disease documented by CT, MRI, X-ray or nuclear exam
             (FDG-PET). Measurable or non-measurable disease must be present outside the area of
             surgical resection. Pleural effusions, ascites and laboratory parameters are not
             acceptable as the only evidence of disease.

          -  Progression after at least one prior platinum-based chemotherapy.

          -  Greater than 3 weeks since surgery and must have recovered from all associated
             toxicities at time of registration.

          -  ANC ≥ 1,500/µl and platelet count ≥ 100,000/µl obtained within 28 days prior to
             registration.

          -  Adequate hepatic function documented by a serum bilirubin ≤ 1.5 times institutional
             upper limit of normal and liver enzymes (SGOT or SGPT) ≤ 2.5 x the institutional upper
             limit of normal obtained within 28 days prior to registration.

          -  Patients requiring lung radiation must have an FEV1 of > 1000 liters obtained within
             28 days prior to registration and must have pulmonary function tests with DLCO.

          -  Zubrod Performance Status of 0,1 or 2.

        Exclusion Criteria:

          -  No prior single-agent, weekly Docetaxel chemotherapy.

          -  Peripheral neuropathy ≥ Grade 1.

          -  Prior malignancy except for the following: adequately treated basal cell or squamous
             cell skin cancer, in situ cervical cancer, adequately treated Stage I or II cancer
             from which the patient is currently in complete remission or other cancer from which
             the patient has been disease-free for 5 years.

          -  Pregnant or nursing women.
Clinical trial NCT00215605 (phase 1, status: completed)
Conditions: lymphoma, cancer, thyroid carcinoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, D09.3
Drugs: xl184
SMILES: COC1=CC2=C(C=C1OC)C(OC1=CC=C(NC(=O)C3(CC3)C(=O)NC3=CC=C(F)C=C3)C=C1)=CC=N2
Eligibility criteria:

        Inclusion Criteria:

          -  Histologically confirmed advanced malignancy (solid tumor or lymphoma) that is
             metastatic or unresectable for which standard curative measures do not exist or are no
             longer effective

          -  Eastern Cooperative Oncology Group (ECOG) performance status </= 2

          -  Life expectancy greater than 3 months

          -  Adequate organ and marrow function

          -  Written informed consent

          -  Use of acceptable methods of contraception during the course of the study and for 3
             months after completion of study

          -  In the MTD expanded cohort: at least 20 subjects with metastatic and/or
             advanced/locally recurrent Medullary Thyroid Cancer not appropriate for surgical
             resection with measurable disease as defined by RECIST

        Exclusion Criteria:

          -  Chemotherapy, immunotherapy or radiation within 4 weeks (or nitrosoureas or mitomycin
             C within 6 weeks) before the first scheduled dose of XL184

          -  Administration of an investigational drug within 30 days of the first dose of XL184

          -  Subject has not recovered from adverse events due to investigational agents or other
             medications administered more than 4 weeks before study enrollment

          -  Known brain metastases

          -  Uncontrolled intercurrent illness

          -  Pregnancy or breastfeeding

          -  Known HIV positive

          -  Known allergy or hypersensitivity to any of the components of the XL184 formulation
Clinical trial NCT01317641 (phase 1/phase 2, status: completed)
Conditions: prostate cancer
ICD codes: C61, D29.1, D40.0, Z15.03, Z80.42, Z85.46, Z12.5
Drugs: odm-201
SMILES: C[C@@H](CN1C=CC(=N1)C1=CC=C(C#N)C(Cl)=C1)NC(=O)C1=NNC(=C1)C(C)O
Eligibility criteria:

        Inclusion Criteria:

          -  Written informed consent

          -  Histologically confirmed adenocarcinoma of prostate

          -  Ongoing androgen deprivation therapy with a LHRH analogue or antagonist or bilateral
             orchiectomy

          -  Progressive metastatic disease

          -  Adequate bone marrow, hepatic, and renal function

        Exclusion Criteria:

          -  Known metastases in the brain

          -  History of other malignancy within the previous 5 years

          -  Known gastrointestinal disease or procedure that affects the absorption

          -  Not able to swallow the study drug
Clinical trial NCT01028911 (phase 1, status: terminated)
Conditions: alzheimer's disease
ICD codes: G30.8, G30.9, G30.0, G30.1
Drugs: pf-03654746, placebo
SMILES: CCNC(=O)[C@H]1C[C@](F)(C1)C1=CC(F)=C(CN2CCCC2)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    this study terminated 27apr2010 due to slow recruitment and the need to use the existing
    information to determine dosing for another study.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Probable Alzheimer's disease

          -  Mini Mental State Examination score 18-26 inclusive

          -  Aged 55-85

        Exclusion Criteria:

          -  Dementia other than Alzheimer's disease

          -  Clinically significant cardiovascular disease in the past 6 months prior to screening

          -  Creatinine clearance <30 mL/min
Clinical trial NCT00005612 (phase 1/phase 2, status: terminated)
Conditions: ovarian cancer
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: carboplatin, cyclophosphamide, etoposide, paclitaxel, topotecan hydrochloride
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, [H][C@@]1(C[C@@H](C)[C@]2([H])CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@]3([H])CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@@]3([H])C(=O)O2)OC)CC[C@@H](OCCO)[C@@H](C1)OC, CC[C@@]1(O)C(=O)OCC2=C1C=C1N(CC3=CC4=C(C=CC(O)=C4CN(C)C)N=C13)C2=O
Reason stopped: 
    low accrual
  
Eligibility criteria:

        DISEASE CHARACTERISTICS: Histologically proven stage IIIC ovarian epithelial cancer
        Chemosensitive to 6-8 courses of standard dose adjuvant chemotherapy (one regimen), such as
        cisplatin or carboplatin in combination with paclitaxel, or any other standard dose regimen
        Residual disease (no greater than 1 cm) following second look laparotomy Ineligible if no
        microscopic disease present following induction chemotherapy OR Histologically proven newly
        diagnosed stage IV ovarian epithelial cancer Achieved at least partial response (PR) (80%
        or greater reduction in tumor by CT scan) following six courses of standard dose
        chemotherapy (one regimen) OR Residual disease (no greater than 1 cm) or no disease
        determined at the time of second look laparotomy OR Histologically proven relapsed ovarian
        epithelial cancer Relapse following standard dose chemotherapy Chemosensitive Achieved at
        least PR after 4-6 courses of salvage chemotherapy (total of 2 regimens) No more than a six
        week interval between completion of standard dose chemotherapy and second look laparotomy

        PATIENT CHARACTERISTICS: Age: 18 to 65 Performance status: ECOG 0 or 1 Life expectancy: Not
        specified Hematopoietic: Not specified Hepatic: Bilirubin no greater than 2.0 mg/dL ALT or
        AST no greater than 2.5 times normal Renal: Creatinine no greater than 2.0 mg/dL OR
        Creatinine clearance at least 60 mL/min Cardiovascular: Ejection fraction at least 50% by
        MUGA scan No severe cardiac dysfunction or major heart disease No angina pectoris No
        ventricular dysrhythmias Essential hypertension allowed if controlled with medication(s)
        Pulmonary: DLCO at least 50% predicted No symptomatic obstructive or restrictive pulmonary
        disease Other: No active infections HIV negative No uncontrolled insulin dependent diabetes
        mellitus No uncompensated major thyroid or adrenal dysfunction No other malignancy within
        the past 5 years except nonmelanomatous skin cancer Not pregnant or nursing Negative
        pregnancy test

        PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: See Disease
        Characteristics No prior topotecan Endocrine therapy: Not specified Radiotherapy: Not
        specified Surgery: See Disease Characteristics Other: No concurrent nitroglycerin
        preparations or antiarrhythmic drugs
Clinical trial NCT00098332 (phase 1, status: completed)
Conditions: lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: forodesine hydrochloride
SMILES: OC[C@H]1N[C@H]([C@H](O)[C@@H]1O)C1=CNC2=C1N=CNC2=O
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Histologically confirmed cutaneous T-cell lymphoma

               -  Refractory to prior treatment

               -  Stage IIA, IIB, III, IVA, or IVB disease

          -  Measurable disease

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-2

        Life expectancy

          -  At least 3 months

        Hematopoietic

          -  Not specified

        Hepatic

          -  AST and/or ALT ≤ 3 times upper limit of normal

          -  Hepatitis B and/or hepatitis C negative

        Renal

          -  Creatinine clearance ≥ 40 mL/min

        Immunologic

          -  Human T-cell lymphotrophic virus type I (HTLV-I) negative

          -  HIV negative

          -  No active serious infection not controlled by antibiotics

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No known impaired absorption of the gastrointestinal tract

          -  No other illness that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  More than 21 days since prior chemotherapy and recovered

        Endocrine therapy

          -  Concurrent topical corticosteroids allowed provided patient remains on a stable dose

        Radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  Not specified

        Other

          -  More than 30 days since prior investigational agents and recovered

          -  No concurrent tanning bed use

          -  No other concurrent therapy for cutaneous T-cell lymphoma
Clinical trial NCT00338182 (phase 1, status: completed)
Conditions: tumors
ICD codes: E88.3, R97.8, C49.A0, C49.A1, C49.A2, C49.A5, C49.A3
Drugs: azd1152 part a, azd1152 part b
SMILES: CCN(CCCOC1=CC=C2C(NC3=CC(CC(=O)NC4=CC=CC(F)=C4)=NN3)=NC=NC2=C1)CCOP(O)(O)=O, CCN(CCCOC1=CC=C2C(NC3=CC(CC(=O)NC4=CC=CC(F)=C4)=NN3)=NC=NC2=C1)CCOP(O)(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  Histological or cytological confirmation of a solid, malignant tumour

          -  At least one measurable or non-measurable site of disease as defined by Response
             Evaluation Criteria in Solid Tumors (RECIST) criteria.

        Exclusion Criteria:

          -  Participation in an investigational drug study within the 21 days prior to therapy or
             those who have not recovered from the effects of an investigational study drug

          -  Recent major surgery within 4 weeks prior to entry into the study
Clinical trial NCT01145885 (phase 1, status: completed)
Conditions: neoplasms
ICD codes: C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2
Drugs: bi 6727
SMILES: [H][C@@]1(CC[C@@]([H])(CC1)N1CCN(CC2CC2)CC1)N=C(O)C1=CC(OC)=C(NC2=NC=C3N(C)C(=O)[C@@]([H])(CC)N(C(C)C)C3=N2)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Inclusion Criteria 1. Patients with histologically or cytologically confirmed
             diagnosis of advanced, non resectable and / or metastatic solid tumour

          -  Inclusion Criteria 2. Male

          -  Inclusion Criteria 3. Age >=18 and =<70 years

          -  Inclusion Criteria 4. Written informed consent

          -  Inclusion Criteria 5. Eastern Cooperative Oncology Group (ECOG) performance score =<2

          -  Inclusion Criteria 6. Recovery from Common Terminology Criteria for Adverse Events
             (CTCAE) Grade >=2 therapy-related toxicities from previous chemo-, hormone-, immuno-,
             or radiotherapy

        Exclusion criteria:

          -  Exclusion Criteria 1. Serious concomitant non-oncological disease considered by the
             investigator

          -  Exclusion Criteria 2. Active infectious disease

          -  Exclusion Criteria 3. Viral hepatitis, Human Immunodeficiency Virus (HIV) infection

          -  Exclusion Criteria 4. Clinical evidence of active brain metastasis during the past 6
             months

          -  Exclusion Criteria 5. Second malignancy currently requiring active therapy

          -  Exclusion Criteria 6. Absolute neutrophil count less than 1,500/mm3

          -  Exclusion Criteria 7. Platelet count less than 100,000/mm3

          -  Exclusion Criteria 8. Total bilirubin greater than 1.5 mg/dL

          -  Exclusion Criteria 9. Aspartate amino transferase (AST) and / or alanine amino
             transferase (ALT) greater than 2.5 times the upper limit of normal (if related to
             liver metastases greater than five times the upper limit of normal)

          -  Exclusion Criteria 10. Serum creatinine greater than 1.5x Upper Limit of Normal (ULN).

          -  Exclusion Criteria 11. Known history of QT/QTcF-prolongation

          -  Exclusion Criteria 12. Patients who are sexually active and having a partner with
             childbearing potential and unwilling to use a medically acceptable method of
             contraception

          -  Exclusion Criteria 13. Treatment with other investigational drugs or participation in
             another clinical trial

          -  Exclusion Criteria 14. Chemo-, radio- immuno-, or molecular-targeted cancer-therapy
             within the past four weeks prior to start of therapy or concomitantly with this trial.
             This restriction does not apply to steroids and bisphosphonates.

          -  Exclusion Criteria 15. Alcohol abuse

          -  Exclusion Criteria 16. Life expectancy less than 12 weeks

          -  Exclusion Criteria 17. Potent Cytochrome P450 enzyme (CYP) 3A4 and P-glycoprotein
             inhibitors or inducers

          -  Exclusion Criteria 18. History of allergy/hypersensitivity
Clinical trial NCT00660972 (phase 1, status: completed)
Conditions: hiv infections
ICD codes: Z21
Drugs: raltegravir, emtricitabine/tenofovir disoproxil fumarate
SMILES: CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1, NC1=NC(=O)N(C=C1F)[C@@H]1CS[C@H](CO)O1
Eligibility criteria:

        Inclusion Criteria:

          -  HIV infected

          -  Antiretroviral treatment naive

          -  Viral load at least 10,000 and less than 300,000 copies/ml within 42 days prior to
             study entry

          -  Agree to use appropriate form of contraception. More information on this criterion can
             be found in the protocol.

        Exclusion Criteria:

          -  Received HIV-specific immunizations within 6 months prior to study entry

          -  Received immunizations within 6 months prior to study entry

          -  Known allergy or sensitivity to study drugs

          -  Any participant with an acute AIDS-defining opportunistic infection (OI) who is not
             clinically stable or who has not been on therapy for the OI for at least 30 days prior
             to study entry

          -  Treatment with immune modulators or any investigational therapy within 30 days prior
             to study entry

          -  Evidence of HIV seroconversion within 6 months prior to study entry

          -  Illness requiring systemic treatment and/or hospitalization

          -  Substance abuse that, in the opinion of the investigator, would interfere with
             adherence to study requirements

          -  Requirement for any current medications that are prohibited with any study medication.
             More information on this criterion can be found in the protocol.

          -  Evidence of any major resistance-associated mutation on any genotype performed prior
             to study entry or at the time of screening. More information on this criterion can be
             found in the protocol.

          -  Abnormal laboratory values. More information on this criterion can be found in the
             protocol.

          -  Pregnant or breastfeeding
Clinical trial NCT00646776 (phase 1, status: completed)
Conditions: antivirals/hiv
ICD codes: B20, Z71.7, O98.72, Z21, O98.73, R75, Z11.4
Drugs: rifabutin, rifabutin + atazanavir + ritonavir
SMILES: NC(=O)C1=NC=CN=C1, CC(C)[C@H](NC(=O)N(C)CC1=CSC(=N1)C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC1=CC=CC=C1)NC(=O)OCC1=CN=CS1)CC1=CC=CC=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Healthy male and female subjects between the ages of 18 to 50 years old with a body
             mass index (BMI) of 18 to 32 kg/m²

          -  Prior to enrollment, subjects must have physical and laboratory test findings within
             the normal limits, and women of childbearing potential (WOCBP) must have a negative
             pregnancy test

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Evidence of organ dysfunction or any clinically significant deviation from normal in
             physical examination, vital signs, electrocardiogram (ECG) or clinical laboratory
             determinations

          -  Use of any prescription drugs or over-the-counter acid controllers within 4 weeks
             prior to study drug administration

          -  Use of any other drugs, including over-the-counter medications of herbal preparations
             within 1 week prior to study drug administration